Infectious Disease Testing Instrumentation Sales

Infectious Disease Testing Instrumentation Sales Market Outlook

The global market for Infectious Disease Testing Instrumentation is projected to reach USD 12.5 billion by 2035, growing at a CAGR of 8.2% during the forecast period of 2025-2035. This growth is mainly driven by an increasing prevalence of infectious diseases worldwide, heightened awareness regarding early diagnosis, and technological advancements in diagnostic tools. The recent pandemic has further accentuated the importance of rapid and accurate testing methods to control the spread of infectious diseases, leading to burgeoning investments from governments and private sectors alike. Additionally, advancements in molecular diagnostics and point-of-care testing are playing a crucial role in driving the market. As healthcare institutions seek to enhance their diagnostic capabilities, the demand for sophisticated instrumentation is anticipated to rise significantly in the coming years.

Growth Factor of the Market

The growth of the Infectious Disease Testing Instrumentation Sales Market can be attributed to several interrelated factors. Firstly, the alarming rise in infectious diseases, including COVID-19, HIV, and tuberculosis, has created an urgent need for advanced diagnostic tools that can deliver quick and reliable results. Secondly, government initiatives to improve healthcare infrastructure and promote disease prevention programs are expected to further boost the demand for testing instrumentation. Thirdly, the advent of innovative technologies such as molecular diagnostics and automated testing solutions is enhancing testing accuracy and reducing turnaround times, making them increasingly appealing to healthcare providers. Additionally, growing awareness about the importance of early diagnosis in effectively managing infectious diseases is also a key driver. Lastly, the rising demand for home-based testing solutions, tailored for both patients and healthcare professionals, is likely to open new avenues for growth in the market.

Key Highlights of the Market

• The market is projected to grow significantly due to the rise in infectious diseases.
• Government initiatives worldwide are pushing for better diagnostic solutions.
• The increasing adoption of advanced technologies in diagnostic testing is reshaping the industry.
• Home-based testing solutions are becoming increasingly popular among consumers.
• Molecular diagnostics are leading the way in innovation and market share.

By Product Type

Molecular Diagnostic Instruments:

Molecular diagnostic instruments are at the forefront of the infectious disease testing instrumentation market. They employ techniques such as PCR, next-generation sequencing, and other nucleic acid amplification methods to detect pathogens at a molecular level. This technology allows for the rapid identification of infectious agents, even in the early stages of an infection, making it invaluable in clinical settings. The need for precise and timely diagnostics, especially in the wake of global pandemics, has led to increasing investments in molecular diagnostics. Furthermore, the ability to detect multiple pathogens simultaneously enhances the efficiency of these instruments, catering to the growing demand for comprehensive testing solutions.

Immunoassay Instruments:

Immunoassay instruments leverage antibody-based techniques to detect and quantify various infectious agents in biological samples. This segment has witnessed substantial growth owing to its wide applicability in both clinical diagnostics and research. The increasing incidence of diseases such as hepatitis, HIV, and sexually transmitted infections has propelled the demand for immunoassay testing. Additionally, advancements in technology have led to the development of more sensitive and specific assays, making these instruments a preferred choice for many laboratories. The convenience of these tests, combined with their ability to provide rapid results, further underscores their significance in the infectious disease testing landscape.

Microbiology Instruments:

Microbiology instruments play a crucial role in the identification and characterization of pathogens. This segment includes equipment such as culture systems, microscopes, and automated systems that facilitate the growth and identification of microorganisms. As the understanding of infectious diseases deepens, the need for accurate and sophisticated microbiological testing is becoming increasingly important. The rise in antibiotic resistance and the subsequent need for proper pathogen identification have amplified the demand for microbiology instruments. Furthermore, innovations such as automated culture systems are streamlining workflows and enhancing the speed of testing, thus driving their adoption in clinical laboratories.

PCR Instruments:

Polymerase Chain Reaction (PCR) instruments are pivotal in the infectious disease testing market, known for their precision and speed in amplifying DNA sequences. Their capacity to detect pathogens at low levels makes them invaluable for diagnosing a range of infections. The PCR segment has experienced substantial growth, particularly during the COVID-19 pandemic, where rapid testing became critical. Technological advancements, such as real-time PCR and digital PCR, are enhancing the sensitivity and specificity of these tests, thereby driving their integration into routine diagnostics. The increasing focus on personalized medicine and targeted therapies also contributes to the growing demand for PCR instruments in infectious disease testing.

Others:

This category encompasses a range of additional diagnostic tools and technologies that do not fall under the primary classifications. It includes serological testing instruments, rapid diagnostic tests (RDTs), and other emerging technologies that are gaining traction in the infectious disease testing market. The diversification of testing methodologies is crucial for addressing the complex landscape of infectious diseases, offering healthcare providers a broader array of diagnostic options. As healthcare systems evolve, these 'other' instruments are expected to gain prominence, driven by the need for flexibility and rapid response capabilities in the face of emerging infectious threats.

By Application

Hospitals:

Hospitals are one of the most significant applications for infectious disease testing instrumentation, serving as the primary location for diagnosing and treating various infectious diseases. The critical need for timely and accurate diagnosis in hospital settings drives the demand for advanced diagnostic tools. Hospitals utilize a wide range of testing instruments to detect infections quickly and effectively, ensuring that patients receive appropriate treatment in a timely manner. The growing number of hospital-acquired infections and the need for regular screening are key factors contributing to the surge in demand for these instruments. Additionally, the integration of laboratory systems with electronic health records is enhancing the efficiency of testing in hospitals, further propelling market growth.

Diagnostic Laboratories:

Diagnostic laboratories, both independent and those affiliated with hospitals, play a fundamental role in the infectious disease testing landscape. These labs are equipped with advanced testing instrumentation to handle a diverse array of infectious agents, providing accurate and reliable results to healthcare providers. The increasing emphasis on preventive healthcare, coupled with the rising incidences of infectious diseases, is driving the demand for high-throughput testing solutions in diagnostic labs. Additionally, the need for specialized testing and the capability to perform complex analyses make diagnostic laboratories an essential segment in the market. As healthcare continues to shift towards a more data-driven approach, the demand for sophisticated laboratory instrumentation is anticipated to grow significantly.

Research Institutes:

Research institutes are vital for advancing the understanding of infectious diseases and developing new testing methodologies. These entities conduct significant amounts of research to explore the epidemiology and pathogenesis of infectious agents, requiring specialized instrumentation for accurate testing and analysis. The increasing focus on infectious disease research, especially in light of recent global health crises, is driving investment in testing instrumentation at research facilities. The collaboration between research institutes and healthcare providers is also becoming increasingly important, leading to innovations that translate directly into clinical practices. As research initiatives expand, the demand for advanced infectious disease testing instruments is expected to rise correspondingly.

Blood Banks:

Blood banks are crucial entities in the healthcare system, responsible for the collection, testing, and distribution of blood and blood products. The demand for infectious disease testing instrumentation in blood banks is driven by the necessity to ensure blood safety and prevent the transmission of infectious agents through transfusions. Rigorous testing for pathogens such as HIV, hepatitis B, and C, and other bloodborne infections is essential for maintaining the integrity of the blood supply. Technological advancements in testing methods are enabling blood banks to conduct these essential tests more efficiently and accurately. As the focus on transfusion safety continues to grow, the demand for advanced testing instrumentation within blood banks is expected to increase.

Others:

This category includes various additional applications of infectious disease testing instrumentation, including public health laboratories, screening centers, and other specialized facilities involved in disease monitoring and control. These applications are becoming increasingly important as the global landscape of infectious diseases continues to evolve. Enhanced surveillance systems to track infectious disease outbreaks necessitate the use of advanced testing instrumentation. The ongoing need for rapid and accessible testing solutions in diverse environments, such as mobile clinics and point-of-care settings, is also contributing to the growth of this segment. As public health initiatives expand, the applications for infectious disease testing instrumentation will continue to diversify and grow.

By Distribution Channel

Direct Sales:

Direct sales represent a significant distribution channel for infectious disease testing instrumentation, where manufacturers sell their products directly to end-users, such as hospitals and laboratories. This channel allows for improved communication and personalized service, enabling manufacturers to offer tailored solutions that meet the specific needs of their clients. The direct sales model is particularly beneficial for complex instrumentation that requires extensive training and support. Additionally, direct relationships foster ongoing collaborations between manufacturers and healthcare providers, driving innovation and improvements in testing technologies. With increasing competition in the market, companies are increasingly focusing on enhancing their direct sales capabilities to better serve their customers and secure market share.

Distributor Sales:

Distributor sales involve third-party companies that purchase infectious disease testing instruments from manufacturers and resell them to end-users. This distribution channel plays a vital role in expanding the reach of testing instrumentation, particularly in regions where manufacturers may not have a direct presence. Distributors often have established relationships with healthcare providers, allowing for smoother logistics and supply chain management. The distributor sales model is advantageous for manufacturers as it allows them to focus on production and innovation while relying on distributors for marketing and sales efforts. As the demand for testing instruments grows, the distributor sales channel is expected to play a critical role in ensuring the widespread availability of these essential tools.

By End User

Hospitals:

Hospitals are one of the primary end-users of infectious disease testing instrumentation, as they require rapid and accurate diagnostics for patient management and treatment. With the increasing burden of infectious diseases, hospitals are investing in advanced testing technologies to enhance their diagnostic capabilities. The need for timely results to guide clinical decisions is paramount in hospital settings, driving the demand for sophisticated testing instruments. Additionally, the integration of diagnostics into electronic health records (EHR) systems is facilitating more streamlined workflows within hospitals, further increasing the utilization of testing instrumentation. As healthcare providers aim to improve patient outcomes, the focus on advanced diagnostics in hospitals is likely to grow exponentially.

Clinical Laboratories:

Clinical laboratories serve as critical hubs for infectious disease testing, providing essential services to healthcare providers and patients. These laboratories rely on a diverse range of testing instrumentation to conduct various assays and analyses. The demand for clinical laboratory testing has surged due to the increasing prevalence of infectious diseases and the need for routine screening in various populations. The integration of automation and robotics in clinical laboratories is enhancing efficiency and accuracy in testing, which in turn drives the adoption of advanced instrumentation. The ongoing evolution of laboratory practices, coupled with the demand for high-quality testing, is expected to propel the growth of this end-user segment significantly.

Research Institutes:

Research institutes are vital end-users of infectious disease testing instrumentation, as they contribute to the understanding and management of infectious diseases through extensive research and innovation. These institutions utilize advanced testing technologies to conduct experiments that lead to breakthroughs in diagnostics and therapeutics. The growing focus on infectious disease research, especially in light of recent global health challenges, is driving investments in testing instrumentation. As research initiatives expand, the demand for cutting-edge laboratory equipment and diagnostic tools is expected to rise, further emphasizing the role of research institutes in the infectious disease testing landscape. Collaborations between research institutes and healthcare providers are also becoming more prevalent, as shared knowledge leads to the development of improved testing solutions.

Blood Banks:

Blood banks represent a significant end-user segment for infectious disease testing instrumentation, as they are responsible for ensuring the safety of the blood supply. Rigorous testing for infectious agents is critical in preventing transmission through transfusions, necessitating advanced testing technologies in blood banks. The increasing awareness of transfusion-related infections is driving the demand for reliable and efficient testing methods. Furthermore, advancements in automation and multiplex testing technologies are enhancing the capabilities of blood banks to screen for multiple pathogens simultaneously, thereby improving efficiency and safety. As the emphasis on transfusion safety grows, the reliance on advanced testing instrumentation in blood banks is expected to continue its upward trajectory.

Others:

This category includes various end-users that contribute to the infectious disease testing instrumentation market, including public health laboratories, screening centers, and governmental health departments. These entities play a crucial role in disease monitoring and control, utilizing testing instruments to track and respond to outbreaks of infectious diseases. The demand for testing solutions in these settings is driven by the need for timely surveillance and proactive measures to halt the spread of infections. The ongoing need for public health initiatives, especially in response to emerging infectious diseases, underscores the importance of this end-user segment. As public health efforts continue to expand and evolve, the demand for infectious disease testing instrumentation across diverse end-user settings is expected to grow significantly.

By Region

The global infectious disease testing instrumentation market is segmented across several regions, each contributing uniquely to the overall market dynamics. North America holds a dominant position, accounting for approximately 40% of the total market share, driven by the high prevalence of infectious diseases and significant investments in healthcare infrastructure. The region is projected to grow at a CAGR of 7.5%, fueled by advancements in diagnostic technologies and increasing initiatives aimed at improving healthcare services. The presence of leading diagnostic companies and continuous research efforts in North America further bolster its market stance, ensuring a continuous flow of innovative testing solutions.

Europe follows closely, accounting for around 30% of the global market. This region is witnessing a growing emphasis on preventive healthcare, with a focus on early diagnosis and surveillance of infectious diseases. The increasing incidence of healthcare-associated infections and the rising demand for efficient laboratory services are driving the growth in Europe. Additionally, countries such as Germany and the UK are investing heavily in enhancing their diagnostic capabilities, which is expected to contribute positively to the market. Asia Pacific is also emerging as a lucrative market, anticipated to grow at a robust CAGR of 9% due to rising healthcare expenditure and an increasing focus on infectious disease management in developing economies.

Opportunities

The infectious disease testing instrumentation market is poised for significant growth, presenting numerous opportunities for players in the industry. One of the most promising opportunities lies in the development and commercialization of point-of-care testing (POCT) devices. As healthcare systems increasingly prioritize accessibility and rapid results, the demand for POCT solutions is surging. These portable and user-friendly devices can deliver immediate results, making them particularly valuable in remote and underserved areas where access to conventional laboratory testing is limited. With the ongoing advancements in mobile health technology and telemedicine, companies that focus on creating effective POCT solutions are likely to capture a significant share of the growing market. Additionally, strategic partnerships between diagnostic manufacturers and healthcare providers can enhance the reach and adoption of these solutions, further driving market growth.

Another avenue of opportunity in the infectious disease testing instrumentation market is the ongoing development of innovative diagnostic technologies. The rapid evolution of molecular diagnostics, digital health tools, and artificial intelligence in healthcare presents a unique chance for companies to invest in research and development. By developing next-generation sequencing technologies or integrating AI-driven analytics into diagnostic workflows, companies can enhance testing accuracy, streamline operations, and improve patient outcomes. Additionally, the increasing focus on personalized medicine and tailored treatment approaches is opening new doors for diagnostic manufacturers to create specialized tests that cater to specific patient populations. As the landscape of infectious disease management continues to transform, companies that prioritize innovation are well-positioned to thrive in this dynamic market.

Threats

Despite the promising growth prospects, the infectious disease testing instrumentation market faces several threats that could impact its trajectory. One of the most significant threats is the increasing competition from emerging market players that offer cost-effective alternatives to traditional diagnostic methods. These competitors can disrupt established players by providing similar testing capabilities at lower price points, which may force larger companies to adjust their pricing strategies and profit margins. Furthermore, the rapid pace of technological advancement poses a challenge, as companies must continually invest in research and development to stay ahead of the curve. Failing to keep up with advancements could result in obsolescence, thereby diminishing market share. Additionally, regulatory hurdles and compliance challenges in various regions can impede market entry and product launch timelines, presenting further risks to companies operating in this space.

Another critical threat to the infectious disease testing instrumentation market is the rising concern over data security and patient privacy. With the increasing integration of digital health technologies and connectivity in diagnostic systems, the risk of data breaches and cyberattacks has become a prominent concern. Ensuring the security of sensitive patient information is paramount, and any lapses in data protection can lead to significant reputational damage and legal ramifications for companies. Furthermore, the evolving landscape of regulations surrounding data privacy, such as the General Data Protection Regulation (GDPR) in Europe, requires ongoing vigilance and adaptation. Companies that fail to prioritize data security may face substantial fines and loss of consumer trust, hindering their growth prospects. As the market evolves, addressing these threats will be essential for sustained success.

Competitor Outlook

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• bioMérieux
• BD (Becton, Dickinson and Company)
• Hologic, Inc.
• Qiagen
• Cepheid
• PerkinElmer
• GenMark Diagnostics
• Danaher Corporation
• Meridian Bioscience
• Abbott Rapid Diagnostics
• Ortho Clinical Diagnostics

The competitive landscape of the infectious disease testing instrumentation market is characterized by the presence of several established players and emerging companies striving to gain market share. Leading companies, such as Roche Diagnostics and Abbott Laboratories, continue to dominate the market through their extensive portfolios of advanced diagnostic solutions. These companies invest significantly in research and development, driving innovation to meet the evolving needs of healthcare providers. Strategic partnerships and collaborations with healthcare institutions are common among these players, enhancing their ability to deliver comprehensive testing solutions. Furthermore, market leaders often focus on expanding their geographical reach and improving accessibility to their products, ensuring their competitive edge in the global market.

In addition to established companies, several emerging players are entering the infectious disease testing instrumentation market, introducing innovative technologies and solutions. These companies are leveraging advancements in molecular diagnostics, artificial intelligence, and point-of-care testing to differentiate themselves from traditional players. By focusing on niche markets and addressing specific gaps in the testing landscape, these emerging firms are gaining traction and capturing the attention of healthcare providers. As the demand for rapid and accurate diagnostics continues to grow, these innovative players are likely to become key contributors to market dynamics.

Some major companies, such as Siemens Healthineers and Thermo Fisher Scientific, are making significant strides in expanding their product offerings and enhancing their service capabilities. Siemens Healthineers, known for its comprehensive range of diagnostic solutions, is continually innovating to improve testing accuracy and efficiency. The company’s focus on digital health technologies and data analytics is positioning it as a leader in the diagnostics space. Similarly, Thermo Fisher Scientific is leveraging its expertise to develop next-generation diagnostic tools that cater to the evolving needs of modern healthcare. By investing in advanced laboratory automation and integrated testing platforms, these companies are setting new standards for infectious disease testing.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Qiagen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Cepheid
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 PerkinElmer
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Hologic, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 bioMérieux
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Danaher Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GenMark Diagnostics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Meridian Bioscience
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Siemens Healthineers
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Abbott Rapid Diagnostics
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ortho Clinical Diagnostics
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Infectious Disease Testing Instrumentation Sales Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Clinical Laboratories
    • 6.1.3 Research Institutes
    • 6.1.4 Blood Banks
    • 6.1.5 Others
  • 6.2 Infectious Disease Testing Instrumentation Sales Market, By Application
    • 6.2.1 Hospitals
    • 6.2.2 Diagnostic Laboratories
    • 6.2.3 Research Institutes
    • 6.2.4 Blood Banks
    • 6.2.5 Others
  • 6.3 Infectious Disease Testing Instrumentation Sales Market, By Product Type
    • 6.3.1 Molecular Diagnostic Instruments
    • 6.3.2 Immunoassay Instruments
    • 6.3.3 Microbiology Instruments
    • 6.3.4 PCR Instruments
    • 6.3.5 Others
  • 6.4 Infectious Disease Testing Instrumentation Sales Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Distributor Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Infectious Disease Testing Instrumentation Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Infectious Disease Testing Instrumentation Sales market is categorized based on

By Product Type

• Molecular Diagnostic Instruments
• Immunoassay Instruments
• Microbiology Instruments
• PCR Instruments
• Others

By Application

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Blood Banks
• Others

By Distribution Channel

• Direct Sales
• Distributor Sales

By End User

• Hospitals
• Clinical Laboratories
• Research Institutes
• Blood Banks
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• bioMérieux
• BD (Becton, Dickinson and Company)
• Hologic, Inc.
• Qiagen
• Cepheid
• PerkinElmer
• GenMark Diagnostics
• Danaher Corporation
• Meridian Bioscience
• Abbott Rapid Diagnostics
• Ortho Clinical Diagnostics